Sanofi Consumer Healthcare India Limited (SANOFICONR) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 reached ₹2,339 million, up 46% year-over-year, driven by strong domestic and export sales.

• Net profit for Q3 2025 was ₹629 million, a 40% increase year-over-year.

• All voluntarily recalled products were successfully relaunched within the year, restoring market presence.

• The company now operates as a distinct legal entity following a demerger effective June 1, 2024.

Financial highlights

• Q3 2025 revenue: ₹2,339 million, up 46% year-over-year.

• Q3 2025 net profit: ₹629 million, up 40% year-over-year.

• Nine months revenue: ₹6,274 million, up 13% year-over-year.

• Nine months profit after tax: up 27% year-over-year.

Outlook and guidance

• Management highlights sustained growth momentum, with a focus on strengthening the diversified portfolio and expanding market presence.